Selpercatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted selpercatinib, while NYE METODER (Norway) did not recommend it.
Assessment has run over 5.5 years, from 26 Jan 2021 at AWMSG (Wales) to 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2023, recommended by 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 33 of 53 records date from 2023 or later.
The programme is broad: 13 distinct indication wordings are recorded for selpercatinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 53 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess selpercatinib, on 26 Jan 2021; NYE METODER (Norway) did not open a file until 20 Oct 2024 — a wide spread of 3.8 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 9 of 35 decisive outcomes narrowed selpercatinib to a subgroup rather than accepting or refusing it outright, at DMC (Denmark), NICE (England) and SMC (Scotland) among others.
13 of the 13 agencies here assessed selpercatinib more than once, G-BA (Germany) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
selpercatinib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for selpercatinib reads 16 recommended, 10 not recommended, 9 no benefit and 9 restricted, with 9 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 18 Jun 2026 | Retsevmo — benefit assessment §35a | added benefit: not proven | source |
| HIRA (South Korea) | 7 May 2026 | 국소 진행성 또는 전이성 RET 융합 - 양성 비소세포폐암 성인 전신요법을 요하는 진행성 또는 전이성 RET- 변이 갑상선수질암 성인 및 만 12 세 이상 소아 | reimbursement appropriate | source |
| DMC (Denmark) | 18 Feb 2026 | Behandling af voksne med RET-fusionspositiv fremskreden ikke-småcellet lungekræft (NSCLC), som ikke tidligere er behandl… | Ikke anbefalet | source |
| SMC (Scotland) | 7 Jul 2025 | As monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if r… | accepted (restricted) | source |
| HAS (France) | 25 Jun 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
48 further decisions for selpercatinib, across 13 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 40 further source documents.
Related molecules
- pralsetinib — divergent outcome (recommended vs not recommended) on a shared indication
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 53 decisions for selpercatinib from 13 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.